---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-116943"
form_type: "8-K"
ticker: "JSPR"
cik: "0001788028"
company_name: "Jasper Therapeutics, Inc."
filed_at: "2025-12-02T23:59:59+00:00"
generated_at: "2026-05-16T15:45:45.622348+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Jasper reports positive ETESIAN asthma data; BEACON investigation clears drug product

## Summary
- Single 180mg briquilimab reduced sputum eosinophils from 10.3% to 2.32% at 6 weeks post-allergen challenge.
- Late asthmatic response FEV1 AUC improved 25.4% at 6 weeks and 23.3% at 12 weeks vs baseline.
- BEACON investigation: no drug product issues; 9 of 10 US patients likely did not have mast cell-driven CSU.
- Briquilimab well-tolerated; no dose-limiting toxicities; safety profile consistent with prior studies.
- Final BEACON data expected Q1 2026; Phase 2b CSU study planned to start mid-2026.

## SEC filing metadata
- accession: 0001213900-25-116943
- form_type: 8-K
- ticker: JSPR
- cik: 0001788028
- company_name: Jasper Therapeutics, Inc.
- filed_at: 2025-12-02T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1788028/000121390025116943/0001213900-25-116943-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1788028/000121390025116943/ea0268071-8k_jasper.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-116943
- JSON: https://secwatch.observer/filing/0001213900-25-116943.json
- Plain text: https://secwatch.observer/filing/0001213900-25-116943.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.